ZORYVE (roflumilast) Foam 0.3%
Seborrheic Dermatitis
Key Facts
About Arcutis Biotherapeutics
Arcutis Biotherapeutics, founded in 2016, is a public biotech company dedicated to meaningful innovation in medical dermatology. It leverages a proprietary topical formulation platform to develop targeted therapies, primarily PDE4 inhibitors, for chronic inflammatory skin conditions. The company has secured six FDA approvals for its ZORYVE franchise and is advancing a diverse pipeline, including a biologic candidate for atopic dermatitis, to address significant unmet patient needs.
View full company profileAbout Arcutis Biotherapeutics
Arcutis Biotherapeutics, founded in 2016, is a public biotech company dedicated to meaningful innovation in medical dermatology. It leverages a proprietary topical formulation platform to develop targeted therapies, primarily PDE4 inhibitors, for chronic inflammatory skin conditions. The company has secured six FDA approvals for its ZORYVE franchise and is advancing a diverse pipeline, including a biologic candidate for atopic dermatitis, to address significant unmet patient needs.
View full company profileAbout Arcutis Biotherapeutics
Arcutis Biotherapeutics, founded in 2016, is a public biotech company dedicated to meaningful innovation in medical dermatology. It leverages a proprietary topical formulation platform to develop targeted therapies, primarily PDE4 inhibitors, for chronic inflammatory skin conditions. The company has secured six FDA approvals for its ZORYVE franchise and is advancing a diverse pipeline, including a biologic candidate for atopic dermatitis, to address significant unmet patient needs.
View full company profileAbout Arcutis Biotherapeutics
Arcutis Biotherapeutics, founded in 2016, is a public biotech company dedicated to meaningful innovation in medical dermatology. It leverages a proprietary topical formulation platform to develop targeted therapies, primarily PDE4 inhibitors, for chronic inflammatory skin conditions. The company has secured six FDA approvals for its ZORYVE franchise and is advancing a diverse pipeline, including a biologic candidate for atopic dermatitis, to address significant unmet patient needs.
View full company profile